Supernus Pharmaceuticals, Inc. (SUPN) DCF Valuation

Supernus Pharmaceuticals, Inc. (SUPN) DCF Valuation

US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ
Supernus Pharmaceuticals, Inc. (SUPN) DCF Valuation
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

Supernus Pharmaceuticals, Inc. (SUPN) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Gain mastery over your Supernus Pharmaceuticals, Inc. (SUPN) valuation analysis using our state-of-the-art DCF Calculator! This Excel template comes preloaded with real (SUPN) data, enabling you to adjust forecasts and assumptions to accurately determine the intrinsic value of Supernus Pharmaceuticals, Inc.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020
AY2
2021
AY3
2022
AY4
2023
AY5
2024
FY1
2025
FY2
2026
FY3
2027
FY4
2028
FY5
2029
Revenue 520.4 579.8 667.2 607.5 661.8 705.6 752.4 802.2 855.3 911.9
Revenue Growth, % 0 11.41 15.09 -8.95 8.94 6.62 6.62 6.62 6.62 6.62
EBITDA 212.4 129.2 153.4 90.0 178.3 180.4 192.4 205.1 218.7 233.2
EBITDA, % 40.82 22.28 23 14.82 26.94 25.57 25.57 25.57 25.57 25.57
Depreciation 20.0 32.6 85.6 84.9 80.4 68.3 72.9 77.7 82.8 88.3
Depreciation, % 3.84 5.62 12.83 13.97 12.15 9.68 9.68 9.68 9.68 9.68
EBIT 192.4 96.6 67.8 5.2 97.9 112.1 119.5 127.4 135.9 144.9
EBIT, % 36.97 16.66 10.16 0.8533 14.79 15.89 15.89 15.89 15.89 15.89
Total Cash 422.5 339.7 461.3 254.9 453.6 450.8 480.6 512.5 546.4 582.6
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 140.9 148.9 165.5 144.2 142.1
Account Receivables, % 27.07 25.69 24.8 23.73 21.47
Inventories 48.3 86.0 91.5 77.4 54.3 83.0 88.4 94.3 100.5 107.2
Inventories, % 9.29 14.83 13.72 12.74 8.2 11.76 11.76 11.76 11.76 11.76
Accounts Payable 6.1 9.3 10.5 2.0 4.6 7.6 8.1 8.6 9.2 9.8
Accounts Payable, % 1.18 1.61 1.58 0.32328 0.69309 1.08 1.08 1.08 1.08 1.08
Capital Expenditure -3.4 -2.0 -.4 -.6 -.7 -1.8 -1.9 -2.0 -2.2 -2.3
Capital Expenditure, % -0.66276 -0.35272 -0.06174708 -0.09069645 -0.10955 -0.2555 -0.2555 -0.2555 -0.2555 -0.2555
Tax Rate, % 24.53 24.53 24.53 24.53 24.53 24.53 24.53 24.53 24.53 24.53
EBITAT 144.8 70.5 67.8 2.5 73.9 83.2 88.7 94.6 100.9 107.6
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -21.7 58.6 132.1 113.7 181.4 93.0 143.2 152.7 162.8 173.6
WACC, % 8.17 8.17 8.19 8.15 8.17 8.17 8.17 8.17 8.17 8.17
PV UFCF
SUM PV UFCF 565.1
Long Term Growth Rate, % 4.00
Free cash flow (T + 1) 181
Terminal Value 4,330
Present Terminal Value 2,924
Enterprise Value 3,489
Net Debt -35
Equity Value 3,524
Diluted Shares Outstanding, MM 56
Equity Value Per Share 62.97

What You Will Get

  • Pre-Filled Financial Model: Supernus Pharmaceuticals' actual data facilitates accurate DCF valuation.
  • Full Forecast Control: Modify revenue growth, profit margins, WACC, and other essential drivers.
  • Instant Calculations: Automatic updates provide immediate results as you adjust inputs.
  • Investor-Ready Template: A polished Excel file crafted for high-quality valuation presentations.
  • Customizable and Reusable: Designed for adaptability, allowing for repeated use in comprehensive forecasts.

Key Features

  • Comprehensive SUPN Data: Pre-filled with Supernus Pharmaceuticals’ historical financials and future projections.
  • Fully Customizable Inputs: Modify revenue growth, profit margins, WACC, tax rates, and capital expenditures.
  • Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
  • Scenario Testing: Develop multiple forecast scenarios to evaluate various valuation outcomes.
  • User-Friendly Design: Intuitive, organized, and suitable for both professionals and novices.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Supernus Pharmaceuticals data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Supernus Pharmaceuticals’ intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose This Calculator for Supernus Pharmaceuticals, Inc. (SUPN)?

  • Accurate Data: Real Supernus financials provide dependable valuation outcomes.
  • Customizable: Tailor key inputs such as growth rates, WACC, and tax rates to align with your forecasts.
  • Time-Saving: Pre-configured calculations save you from building from the ground up.
  • Professional-Grade Tool: Crafted for investors, analysts, and consultants in the pharmaceutical sector.
  • User-Friendly: Easy-to-navigate design and clear instructions ensure accessibility for all users.

Who Should Use Supernus Pharmaceuticals, Inc. (SUPN)?

  • Investors: Gain insights into pharmaceutical investments with detailed market analysis.
  • Healthcare Analysts: Utilize comprehensive data to evaluate drug performance and market potential.
  • Consultants: Tailor reports and presentations using Supernus' strategic insights for client needs.
  • Pharmaceutical Enthusiasts: Enhance your knowledge of drug development and market trends with real-life case studies.
  • Educators and Students: Leverage this information as a resource for learning about the pharmaceutical industry.

What the Template Contains

  • Comprehensive DCF Model: Editable template featuring detailed valuation calculations tailored for Supernus Pharmaceuticals, Inc. (SUPN).
  • Real-World Data: Supernus’s historical and projected financials preloaded for in-depth analysis.
  • Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
  • Financial Statements: Complete annual and quarterly breakdowns providing deeper insights into the company's performance.
  • Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to Supernus Pharmaceuticals, Inc. (SUPN).
  • Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results to aid decision-making.


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.